Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan
{"title":"在癌症诊断的情况下,爱尔兰皮肤科顾问治疗严重牛皮癣的处方偏好评估。","authors":"Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan","doi":"10.1007/s11845-025-04113-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.</p><p><strong>Methods: </strong>An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.</p><p><strong>Results: </strong>In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).</p><p><strong>Conclusion: </strong>In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.</p>","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.\",\"authors\":\"Stephanie Bowe, Michelle Murphy, John Bourke, Caitriona Ryan\",\"doi\":\"10.1007/s11845-025-04113-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.</p><p><strong>Methods: </strong>An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.</p><p><strong>Results: </strong>In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).</p><p><strong>Conclusion: </strong>In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.</p>\",\"PeriodicalId\":14507,\"journal\":{\"name\":\"Irish Journal of Medical Science\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Irish Journal of Medical Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11845-025-04113-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-025-04113-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.
Aim: We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.
Methods: An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.
Results: In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).
Conclusion: In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.
期刊介绍:
The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker.
The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.